Results 251 to 260 of about 2,614,131 (297)

The standardization of estrogen receptors

The Journal of Steroid Biochemistry and Molecular Biology, 1993
Tumour estrogen receptor (ER) status may determine the medical treatment of a patient with breast cancer; yet inter-laboratory results can vary markedly, particularly when absolute cut-offs in fmol/mg cytosol protein are used. The use of standardized log units is proposed to permit greater inter-laboratory comparability.
B.G. Mobbs, David R. McCready, Maureen E. Trudeau, Teik Chye Ooi, Carol Sawka, Eugene R. Tustanoff, Eamonn D. Ryan, H. Lavina A. Lickley, Wedad Hanna, Judy-Anne W. Chapman, Kathleen I. Pritchard, Donald J.A. Sutherland   +11 more
openaire   +3 more sources

Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor

Seminars in Oncology, 2003
Fulvestrant, a novel antiestrogen classified as an estrogen receptor antagonist without known agonist effects, was recently approved in the United States for the treatment of postmenopausal, hormone receptor-positive women with progressive metastatic breast cancer after antiestrogen therapy.
openaire   +3 more sources

Estrogen and estrogen receptors in thyroid carcinomas

Journal of Surgical Oncology, 1991
AbstractThyroid tissues, composed of normal thyroid (10 cases), Graves' thyroid (4), and papillary carcinoma (10), were measured for the presence of receptors for estrogen (ER) using an enzyme‐immunoassay method. The mean value of ER in papillary carcinoma tissues (4.0 ± 3.6 fmol/mg protein) was higher than that in normal thyroid tissues (0.8 ± 0.4 ...
Akitaka Nonomura, Yuji Mizukami, Masakuni Noguchi, Fujitsugu Matsubara, Takuma Hashimoto, Takatoshi Michigishi   +5 more
openaire   +3 more sources

The Role of Estrogen and Estrogen Receptors in Chemoresistance

Current Medicinal Chemistry, 2011
Drug resistance is one of the major obstacles limiting the success of cancer chemotherapy. Biological mechanisms contributing to drug resistance may be present de novo and related to inherent features or may be raised after exposure to anticancer drugs. In recent years, both clinical observations and experimental studies suggested that steroid hormones
H Zhang, Weimin Fan, Meihua Sui
openaire   +3 more sources

The histochemistry of estrogen receptors

Histochemistry, 1981
Estrogen receptors in frozen section of the rat uterus were demonstrated by a radiolabeled ligand binding technique. The bound hormone was extracted with ethanol and measured by liquid scintillation. The binding of 3H-estradiol-17 beta at various molar concentrations was inhibited by a 100-fold excess of DES, and the bound 3H-estradiol resisted ...
openaire   +3 more sources

Biological Role of Estrogen and Estrogen Receptors

Critical Reviews in Biochemistry and Molecular Biology, 2002
(2002). Biological Role of Estrogen and Estrogen Receptors. Critical Reviews in Biochemistry and Molecular Biology: Vol. 37, No. 1, pp. 1-28.
Jan-Åke Gustafsson, Stefan Nilsson
openaire   +3 more sources

Estrogen and estrogen receptors of breast cancer

Journal of Surgical Oncology, 1975
AbstractHuman breast cancer can be divided into a group that contains specific receptor sites for estrogen and a group without such specific estrogen‐binding sites. The presence of specific estrogen receptors in some tumors indicating hormonal dependency has been shown to be of predictive value for endocrine treatment.
Howard H. Sky-Peck, Velayudan Sahadevan, Steven G. Economou, Charles P. Perlia   +3 more
openaire   +3 more sources

An update on estrogen receptors

Seminars in Perinatology, 2000
The discovery of a second estrogen receptor (ER), ERbeta, has led to a complete change in our views on estrogen action. The previous dogmatic view that ERalpha represented the only estrogen receptor led to a static and simplistic concept of mechanisms of estrogen action with conceptual limitations in the development of novel estrogenic and ...
openaire   +3 more sources

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Archives of Pathology & Laboratory Medicine, 2010
PURPOSE To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers.
M. E. Hammond, Daniel F. Hayes, M. Dowsett, D. Allred, K. Hagerty, S. Badve, P. Fitzgibbons, G. Francis, Neil S. Goldstein, M. Hayes, David G. Hicks, S. Lester, R. Love, P. Mangu, L. McShane, K. Miller, C. K. Osborne, S. Paik, J. Perlmutter, A. Rhodes, H. Sasano, Jared N. Schwartz, F. C. Sweep, S. Taube, E. Torlakovic, P. Valenstein, G. Viale, D. Visscher, T. Wheeler, R. B. Williams, J. Wittliff, Antonio C. Wolff   +31 more
semanticscholar   +1 more source

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

New England Journal of Medicine, 1989
We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary nodes, and estrogen-receptor-positive (greater than or ...
B. Fisher, J. Costantino, C. Redmond, R. Poisson, D. Bowman, J. Couture, N. Dimitrov, N. Wolmark, D. Wickerham, Edwin R. Fisher, R. Margolese, A. Robidoux, H. Shibata, J. Terz, A. Paterson, M. Feldman, W. Farrar, James Evans, H. Lickley, Mary Ketner   +19 more
semanticscholar   +1 more source